

## 4DMEDICAL SECURES COMMERCIAL CONTRACT WITH MULTINATIONAL PHARMACEUTICAL COMPANY

---

### Highlights

- 4DMedical has signed a contract with multinational pharmaceutical company Novartis for the commercial use of XV Lung Ventilation Analysis Software (XV LVAS™)
  - XV LVAS will be used to assess patient outcomes in a clinical program focused on validating pharmaceutical therapies to treat Chronic Obstructive Pulmonary Disease (COPD)
  - The clinical program will be conducted at the University of Miami in the U.S., as part of 4DMedical's Functional Lung Imaging Research Program
  - This contract represents the first commercial use of XV LVAS in the pharmaceutical industry
- 

**9 August 2021:** 4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company"), a medical technology company focused on commercialising its FDA cleared and TGA approved respiratory imaging platform, is pleased to announce that it has signed a contract with multinational pharmaceutical company, Novartis, for the commercial use of its XV Lung Ventilation Analysis Software (XV LVAS™).

The contract represents the first commercial use of XV LVAS in the pharmaceutical industry and will be used to assess patient outcomes in a clinical program focused on novel therapies to treat Chronic Obstructive Pulmonary Disease (COPD) – the third highest cause of death in the world<sup>1</sup>.

The clinical program will be conducted at the University of Miami in the U.S., under the Company's Functional Lung Imaging Research Program to advance breakthrough lung technologies.

### 4DMedical Founder and CEO, Andreas Fouras, said:

"We are extremely pleased to have secured our first pharmaceutical customer for our XV LVAS technology. Novartis is one of the largest pharmaceutical companies in the world and we are proud to assist them with the development of breakthrough COPD therapies. The program will further validate the application of XV LVAS to improving the lives of those living with COPD, which remains a key indication for the Company's technology. Whilst the contract is not substantial in terms of revenue at this stage, it also represents the beginning of our commercial relationship with Novartis and expands our commercial product offering to the pharmaceutical and medical device industries."

### ENDS

Authorised on behalf of the 4DMedical Board of Directors by Andreas Fouras, Managing Director & CEO.

### Contacts:

#### *Corporate*

Charlene Stahr  
Company Secretary  
companysecretary@4dmedical.com

#### *Investor*

Simon Hinsley  
+ 61 401 809 653  
shinsley@4dmedical.com

#### *Media*

Matthew Wright  
+ 61 451 896 420  
matt@nwrcommunications.com.au

---

<sup>1</sup> [https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-\(copd\)](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd))

## About 4DMedical:

Based in Melbourne, Australia and Los Angeles, U.S., 4DMedical was founded in 2012 and is listed on the Australian Securities Exchange (ASX:4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnosis is a US\$31 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.